Merger will generate single center of excellence under Sepracor name.
Dainippon Sumitomo Pharma (DSP) is to merge its U.S.-based Dainippon Sumitomo Pharma America subsidiary into Sepracor, which DSP acquired for $2.6 billion in cash during October 2009.
DSP says that merging its two North American businesses will consolidate its operations in the region into one combined Center of Excellence as well as facilitate operational efficiencies. Sepracor’s commercial organization in the U.S. reportedly includes about 1,200 sales professionals who concentrate on primary care physicians and specialists.
DSP also announced the immediate resignation of Adrian Adams as president, CEO, and director of Sepracor and as executive officer of DSP. Saburo Hamanaka, currently director of Sepracor, will take over as the company’s chairman. Mark Iwicki, Sepracor’s existing vp and chief commercial officer, has been appointed president, COO, and director.